Results 211 to 220 of about 5,019 (231)

T-cell engaging bispecific antibody therapy

2022
Patty A. Culp, Jeremiah D. Degenhardt, Danielle E. Dettling, Chad May   +3 more
openaire   +1 more source

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future Oncology, 2022
Valentina Gambardella, Martin Wermke, Taofeek Owonikoko   +2 more
exaly  

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody

Translational Oncology, 2021
Dimiter Dimitrov, John Mellors, Xianglei Liu   +2 more
exaly  

Tumor flare with T-cell-engaging bispecific antibodies

Leukemia & Lymphoma
Carmelo Carlo-Stella, Michael J. Dickinson, Gloria Iacoboni, Cecilia Carpio, Natalie Dimier, Martin Weisser, Antonia Kwan, Cristiano Ferlini   +7 more
openaire   +2 more sources

BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS

2014
BAKKER ALEXANDER BERTHOLD HENDRIK, VAN LOO PIETER FOKKO, LOGTENBERG TON   +2 more
openaire   +6 more sources

BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

2017
RAUM TOBIAS, MÜNZ MARKUS, BROZY JOHANNES, KUFER PETER, HOFFMANN PATRICK, FRIEDRICH MATTHIAS, RATTEL BENNO, BOGNER PAMELA, WOLF ANDREAS, POMPE CORNELIUS   +9 more
openaire   +4 more sources

FORMULATION FOR BISPECIFIC T-CELL ENGAGERS (BITES)

2014
OLBRICH CARSTEN, BUNTE THOMAS, WINTER JONAS, PETERS JÖRG, TRILL THOMAS   +4 more
openaire   +3 more sources

Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia

British Journal of Haematology, 2019
Solange Paredes-Moscosso, Rachel Evans
exaly  

Characterization of Bispecific T-cell Engager (BiTE®) Antibodies with a High-Capacity T-cell Dependent Cellular Cytotoxicity (TDCC) Assay

SLAS Discovery, 2015
exaly  

DOSING OF BISPECIFIC T CELL ENGAGER

2020
openaire   +3 more sources